Novonesis AS — Earnings Release 2016

Aug 10, 2016

2016 full-year earnings outlook maintained; organic sales outlook adjusted to
2-4%

In the first half of 2016, sales grew by 3% organically and were flat in DKK
compared with the first half of 2015. EBIT was on par, and the EBIT margin was
27.2%, also on par with the first half of 2015. Adjusting for the restructuring
costs in Q1, the EBIT margin would have expanded to above 28% and EBIT growth
to around 4% compared with the first half of 2015. Net profit grew by 8%. Net
investments were DKK 542 million, free cash flow before acquisitions was DKK
1,354 million and ROIC (incl. goodwill) was 25.4%.

The outlook for full-year organic sales growth is adjusted to 2-4%, down from
previously 3-5%. The adjustment reflects uncertainty in most of the industries
in which Novozymes operates. The outlook for sales in DKK is unchanged. The
outlook for each of EBIT, EBIT margin, net profit, net investments, free cash
flow and ROIC is also unchanged.

Peder Holk Nielsen, President & CEO of Novozymes, comments: “Our business
improved in the second quarter. We delivered strong earnings, and we increased
our sales growth although we had aimed higher. We're on track to reach our
full-year profit target, but we adjust our sales expectations due to the
performance in the second quarter and the uncertainty facing many of our
markets. Our pipeline of sustainable biological solutions remains strong, and
we'll soon launch exciting, new innovation in BioAg.”

Please read the full announcement in PDF format